据生物制药公司BridgeBio于11月22日宣布，美国食品药品监督管理局（FDA）批准了Attruby (acoramidis)，用于治疗患有ATTR-CM的成年人，以减少心血管死亡和心血管相关的住院治疗。新闻稿中指出，Attruby是第一个也是唯一一个药物标签上标明TTR 接近完全稳定（≥90％） 的药物。

Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO)的口服药物Attruby™ (acoramidis)获得美国食品和药物管理局 (FDA)批准，用于治疗成年ATTR-CM患者，旨在降低心血管死亡和住院率。这一批准是基于ATTRibute-CM第3期研究的积极结果。受此消息影响，BridgeBio股价上涨25%。

BridgeBio Pharma的Attruby提前获批和强有力的标签，加上其有利的定价和预期的广泛使用，表明公司的市场表现前景乐观。该药物在其治疗领域对患者护理和治疗选择的潜在重大影响，现在成为投资者和行业观察者关注的焦点。

The U.S. Food and Drug Administration has approved a drug developed at Stanford Medicine that offers hope to people diagnosed ...

The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...

11/23，FDA 批准 BridgeBio Pharma $BridgeBio Pharma(BBIO)$ 的 Attruby (acoramidis) 用于降低转甲状腺素蛋白淀粉样心肌病 (ATTR-CM) 患者的心血管死亡和心血管相关住院率，与辉瑞的 tafamidis 展开直接竞争，后者具有相同的作用机制，但批准的适应症更有限。 Attruby 是一种口服 TTR 稳定剂，FDA的批准称该 ...

2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...

The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...

BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved ...

Attruby (acoramidis) is a small molecule approved to treat adults with transthyretin amyloid cardiomyopathy. It will have a ...

Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer ...